Adverse Drug Reactions in Intensive / Initial Phase of Antitubercular Treatment in Patients of Tuberculosis

This study evaluated the incidence of adverse drug reactions ADRs during the intensive phase of antitubercular treatment ATT in tuberculosis patients. Over two years, 132 patients were monitored using Naranjos Algorithm and the Modified Hartwig and Siegel scale to assess ADR causality and severity. The results indicated that 37.88% of patients experienced ADRs, with hepatitis 38% and gastritis 32% being the most common. Extrapulmonary TB patients showed a higher ADR rate 55.26% compared to pulmonary TB patients 32.18%. DRTB patients had an ADR incidence of 88.89%, compared to 34.15% in DSTB. Most ADRs 48% occurred in the first week of treatment, emphasizing the need for early monitoring. The majority were moderate in severity, and 48% required treatment adjustments. Close monitoring during the early treatment phase is critical for managing ADRs and ensuring treatment adherence.